HLHaiwei Li

Haiwei Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Haiwei Li has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Real-World Adverse Event Patterns of a Dual-Chamber Leadless Pacemaker System: A Descriptive Analysis of the FDA MAUDE Database

    by Yilun Tian, Jieruo Chen, Cuicui Feng, Ying Li, Zichao Cheng, Hua He, Haiwei Li

  • Open Access

    Cardiac pacing in congenitally corrected transposition of the great arteries: technique, challenges, and outcome

    by Haiwei Li, Jieruo Chen, Fei Hang, Weiping Sun, Wenlong Dai, Yilun Tian, Hongkai Zhang, Liting Cheng, Huanfu Liu, Die Hu, et al.

  • Magnetically gated millimeter-scale capsule power system for leadless electrotherapy

    by Feiyao Yang, Yu Tian, Enyi Zhang, Lixue Yang, Ziyue You, Puguang Peng, Han Qian, Yan Du, Haiwei Li, Yongquan Wu, et al.

    Temporary cardiac pacing is indispensable for bridging transient bradyarrhythmic indications over days to weeks, yet existing systems remain constrained by device dimensions, surgical complexity, patient burden, and intrinsic operational principles. Here, these challenges are addressed through a millimeter-scale capsule power system with magnetically gated activation via a reed switch, which eliminates the stringent orientation and implantation-depth requirements of optically controlled approaches. In contrast to conventional reed switch-based pacemakers, this capsule system extends the functionality of the reed switch by integrating electrode materials directly onto its surface, thereby enabling a monolithic miniaturized architecture. Pulsed magnetic fields wirelessly actuate intermittent switching, enabling controlled discharge, with robust cardiac pacing demonstrated in large animals. A proof-of-concept closed-loop system is further realized, establishing the feasibility of future integration with a wearable electronic module to enable autonomous electrotherapy upon arrhythmia detection. Collectively, this strategy addresses a key limitation in temporary pacing and may provide a versatile framework for the development of temporary electrotherapeutic systems across cardiac, neural, and regenerative applications.

  • Open Access

    Clinical Utility of the 4S-AF Scheme in Predicting Atrial Fibrillation Recurrence after Radiofrequency Catheter Ablation

    by Naiyuan Cui, Haiwei Li, Weiping Sun, Zefeng Wang, Zhongyu Yuan, Botao Zhu, Yutong Liu, Huanfu Liu, Yongquan Wu, Xiaoping Zhang

    Background: The 4S-AF scheme, which comprises four domains related to atrial fibrillation (AF), stroke risk (St), symptom severity (Sy), severity of AF burden (Sb), and substrate (Su), represents a novel approach for structurally characterizing AF. This study aimed to assess the clinical utility of the scheme in predicting AF recurrence following radiofrequency catheter ablation (RFCA). Methods: We prospectively enrolled 345 consecutive patients with AF who underwent initial RFCA between January 2019 and December 2019. The 4S-AF scheme score was calculated and used to characterize AF. The primary outcome assessed was AF recurrence after RFCA, defined as any documented atrial tachyarrhythmia episode lasting at least 30 seconds. Results: In total, 345 patients (age 61 (interquartile range (IQR): 53–68) years, 34.2% female, 70.7% paroxysmal AF) were analyzed. The median duration of AF history was 12 (IQR: 3–36) months, and the median number of comorbidities was 2 (IQR: 1–3), and 157 (45.5%) patients had left atrial enlargement. During a median follow-up period of 28 (IQR: 13–37) months, AF recurrence occurred in 34.4% of patients. After eliminating the Sy and St domains, both the 4S-AF scheme (hazard ratio (HR) 1.38, 95% confidence interval (CI): 1.19–1.59, p < 0.001) and severity of burden and substrate of atrial fibrillation (2S-AF) scheme scores (HR 1.59, 95% CI: 1.33–1.89, p < 0.001) were independent predictors of AF recurrence following RFCA. For each domain, we found that the independent predictors were Sb (HR 1.84, 95% CI: 1.25–2.72, p = 0.002) and Su (HR 1.71, 95% CI: 1.36–2.14, p < 0.001). Furthermore, the 4S-AF (area under the curve (AUC) 65.2%, 95% CI: 59.3–71.1) and 2S-AF scheme score (AUC 66.2%, 95% CI: 60.2–72.1) had a modest ability to predict AF recurrence after RFCA. Conclusions: The novel 4S-AF scheme is feasible for evaluating and characterizing AF patients who undergo RFCA. A higher 4S-AF scheme score is independently associated with AF recurrence after RFCA. However, the ability of the 4S-AF scheme to discriminate between patients at high risk of recurrence was limited.


  • Open Access

    Sinus node dysfunction after radiofrequency catheter ablation of atrial flutter: A case report

    by Haiwei Li, Zefeng Wang, Yongquan Wu

    Atrial flutter (AFL) is the second most common atrial tachyarrhythmia after atrial fibrillation. Catheter ablation (CA) for typical AFL is well‐established and has a high success rate and adequate safety. However, sick sinus syndrome (SSS) occasionally occurs when long‐term, persistent AFL is terminated by ablation. Sinus node function cannot be assessed during AFL, and the preoperative prediction of underlying SSS has not yet been investigated. When this situation occurs, pacemaker implantation is often necessary. Here, we report a case of SSS after persistent AFL CA.